RPS4X

RPS4X encodes ribosomal protein S4 (X-linked) and was first defined functionally as a gene required for cell cycle progression through G1 and the initiation of DNA synthesis, established by complementation of the temperature-sensitive G1-arrest mutant tsBN63 (PMID:1795030). It is one of the genes that escapes X chromosome inactivation, with mRNA levels scaling with X chromosome gene copy number across numerical and structural aberrations (PMID:1587534); it maps physically adjacent to the X inactivation center in Xq13 alongside XIST and PHKA1 (PMID:8401491). Despite early speculation, RPS4X haploinsufficiency does not underlie Ullrich-Turner syndrome, as i(Xq) patient fibroblasts carrying three copies show elevated rather than reduced RPS4X mRNA (PMID:8557258). Beyond its ribosomal dosage role, RPS4X physically associates with SLFN11, an interaction that blocks mTOR signaling and constrains hepatocellular carcinoma proliferation, migration, and invasion in an RPS4X-dependent manner (PMID:32292519). No structural or biochemical mechanism connecting RPS4X to mTOR regulation or to tumor stemness has been characterized in the available corpus.

1. 1991 High

   Established that RPS4X has a function beyond mere structural ribosomal residence by showing it is required to traverse G1 and begin DNA synthesis.

   Evidence DNA-mediated gene transfer complementation of the temperature-sensitive G1-arrest mutant tsBN63 with cloned cDNA, confirmed by sequencing

   PMID:1795030

   Open questions at the time

   • Does not define whether the cell cycle requirement reflects general translational capacity or a specific extra-ribosomal function
   • No molecular partners or substrates identified
2. 1992 Medium

   Answered whether RPS4X is subject to X inactivation, showing its expression is dosage-sensitive to X chromosome copy number, which framed its candidacy for X-aneuploidy phenotypes.

   Evidence mRNA quantification in fibroblast lines with varying X chromosome complements including Turner syndrome aberrations

   PMID:1587534

   Open questions at the time

   • Correlation of mRNA with copy number does not establish a phenotypic consequence
   • Single lab
3. 1993 Medium

   Placed RPS4X in genomic context by mapping it physically adjacent to the X inactivation center, providing structural rationale for its escape from inactivation.

   Evidence YAC contig and rare-cutter restriction mapping with CpG island and orientation analysis in Xq13

   PMID:8401491

   Open questions at the time

   • Mapping does not establish a mechanism for escape from inactivation
   • No functional link to neighboring genes
4. 1996 Medium

   Resolved whether RPS4X dosage causes Turner syndrome by demonstrating that i(Xq) patients have increased, not decreased, RPS4X mRNA, excluding haploinsufficiency as the etiology.

   Evidence mRNA quantification in karyotypically defined Ullrich-Turner syndrome fibroblasts

   PMID:8557258

   Open questions at the time

   • Negative result; does not exclude other dosage-sensitive genes
   • Single lab
5. 2020 Medium

   Identified a direct protein partner and signaling output for RPS4X, showing it binds SLFN11 to block mTOR signaling and mediate suppression of hepatocellular carcinoma.

   Evidence Co-IP and LC-MS/MS identification, reciprocal Co-IP, immunofluorescence, loss/gain-of-function assays, and orthotopic xenografts with mTOR readout

   PMID:32292519

   Open questions at the time

   • Molecular mechanism by which the SLFN11-RPS4X interaction blocks mTOR is undefined
   • Whether this is a ribosome-dependent or extra-ribosomal activity is unresolved
   • Single lab
6. 2021 Low

   Extended the RPS4X-mTOR axis to a second cancer context by linking GTF2E2 to RPS4X and lung adenocarcinoma growth.

   Evidence LC-MS/MS shotgun proteomics, shRNA knockdown with proliferation/migration/invasion assays, xenografts, and mTOR pathway analysis

   PMID:33757492

   Open questions at the time

   • Interaction not confirmed by reciprocal Co-IP for RPS4X
   • RPS4X mechanistic role inferred indirectly
   • Single lab
7. 2024 Low

   Implicated RPS4X in regulation of tumor cell stemness, placing it upstream of CD44-associated stemness in colorectal cancer.

   Evidence shRNA/siRNA knockdown with stemness assays, in vivo tumor models, and tumor microarray correlation with CD44

   PMID:38439884

   Open questions at the time

   • No direct biochemical mechanism for RPS4X in stemness identified
   • Correlation with CD44 does not establish causality
   • Single lab

• It remains unresolved whether RPS4X's cell cycle and cancer-associated functions are extra-ribosomal activities or downstream consequences of its structural role in translational capacity.
• No structural model of RPS4X interactions
• Mechanism of mTOR pathway modulation undefined
• No reconciliation of dosage-based and partner-based functions